74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ovid therapeutics Inc
Closed
SectorHealthcare
1.63 18.98
Overview
Share price change
24h
Min
1.34
Max
1.67
Income | 5.6M -4.7M |
|---|---|
Sales | 6.1M 6.3M |
Profit margin | -74.681 |
Employees | 23 |
EBITDA | 7.3M -5.1M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +148.18% upside |
Next Earnings | 10 Nov 2025 |
|---|
Market Cap | 84M 123M |
|---|---|
Previous open | -17.35 |
Previous close | 1.63 |
News Sentiment
By Acuity
61%
39%
324 / 371 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Ovid therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ovid therapeutics Inc Forecast
Price Target
By TipRanks
148.18% upside
12 Months Forecast
Average 3.4 USD 148.18%
High 5.5 USD
Low 1.5 USD
Based on 7 Wall Street analysts offering 12 month price targets forOvid therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
324 / 371 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ovid therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Live chat